RecruitingPsoriatic ArthritisAxial Spondyloarthritis

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

Eligible age

18+ yrs

Accepts

All genders

Locations

15 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.

Sponsor: UCB Biopharma SRL

✓ 1. Be 18+ years old and legally able to consent
✓ 2. Have active psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), suitable for bimekizumab treatment
✓ 3. Weigh between 45-100 kg (females) or 50-100 kg (males).
✓ 4. Be biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve or have stopped bDMARDs ≥3 months or 5 half-lives ago

✕ 1. Serious organ system disorders (e.g., heart, liver, kidney, gastrointestinal, neuro)
✕ 2. Severe psychiatric issues or substance abuse in the past year
✕ 3. Recent or chronic infections, including tuberculosis (TB) or nontuberculous mycobacterium (NTMB)
✕ 4. Other inflammatory diseases (e.g., rheumatoid arthritis (RA), lupus, inflammatory bowel disease (IBD))
✕ 5. Recent live vaccines (within 8 weeks) or Bacillus Calmette-Guerin (BCG) (within 1 year)
✕ 6. Recent use of glucagon-like peptide-1 (GLP-1) agonists (within 28 weeks)